3490-50-4

Usage

Uses

Used in Pharmaceutical Applications:
[2-(4-cyanophenyl)-2-oxoethylidene]diazenium is used as a pharmaceutical agent for its nitric oxide-releasing properties. Nitric oxide is a signaling molecule that plays a crucial role in various physiological processes, including vasodilation, neurotransmission, and immune response regulation. [2-(4-cyanophenyl)-2-oxoethylidene]diazenium's ability to release nitric oxide may provide therapeutic benefits in treating conditions related to nitric oxide dysregulation.
Used in Medicinal Chemistry Research:
[2-(4-cyanophenyl)-2-oxoethylidene]diazenium is used as a research tool in medicinal chemistry for its potential to develop new drugs targeting nitric oxide pathways. The cyanophenyl group in the compound may offer opportunities for structural modifications and optimization to enhance its biological activity and pharmacological properties.
Used in Drug Delivery Systems:
In the field of drug delivery, [2-(4-cyanophenyl)-2-oxoethylidene]diazenium can be used as a component in the development of novel drug delivery systems. Its nitric oxide-releasing properties and cyanophenyl group may enable the design of targeted drug delivery systems that can improve the bioavailability and therapeutic efficacy of the compound.
Used in Chemical Synthesis:
[2-(4-cyanophenyl)-2-oxoethylidene]diazenium can be used as a synthetic building block in the development of new chemical compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals. The cyanophenyl group and diazenium structure provide opportunities for further chemical modifications and the creation of new molecules with desired properties.

Upstream product

• 186581-53-3 diazomethane 
• 6068-72-0 4-cyanobenzoyl chlorIde 
• 20099-89-2 4-Cyanophenacyl bromide 

Downstream Products

• 74048-07-0 4-(2-methyl-oxazol-5-yl)-benzonitrile 
• 60695-12-7 α-ethoxy-p-cyanoacetophenone 
• 60695-16-1 4-Cyano-α-benzyloxyacetophenon 
• 76597-76-7 N--L-alanyl-L-phenylalanylpyrrolidine 
• 76597-73-4 N--L-phenylalanylpyrrolidine 
• 76597-66-5 4-(chloroacetyl)benzoic acid chloride 
• 76597-65-4 4-chloroacetyl-benzoic acid 
• 58784-39-7 4-cyanophenylketene 
• 40805-50-3 4-(2-chloroacetyl)benzenecarbonitrile 

Relevant academic research and scientific papers

Phosphoric Acid Catalyzed [4 + 1]-Cycloannulation Reaction of ortho-Quinone Methides and Diazoketones: Catalytic, Enantioselective Access toward cis-2,3-Dihydrobenzofurans

A highly straightforward route to enantiomerically highly enriched cis-2,3-dihydrobenzofurans has been achieved via addition of α-diazocarbonyl compounds to in situ generated o-QMs catalyzed by a chiral Br?nsted acid. This catalytic strategy provides a direct access to 2,3-dihydrobenzofurans in high yields and with up to 91:9 dr and 99:1 er at ambient temperature. Moreover, a unique phenonium-type rearrangement accounts for product formation with an inverted 2,3-substitution pattern.

Tandem Synthesis of α-Diazoketones from 1,3-Diketones

A highly efficient synthesis of α-diazoketone was achieved by simply stirring the mixture of 1,3-diketone, TsN3, and MeNH2 in EtOH. It was a tandem reaction including a novel primary amine-catalyzed Regitz diazo transfer of 1,3-diket

Amination of phenylketene revisit. Substituent effect on reactivity

The asymmetric stretching frequencies of the ketene group of the m,p-substituted phenylketenes were found to be correlated with σ The substituent effects for the second-order rate constants of phenylketenes with various amines were not correlated linearly

Potential Thyroliberin Affinity Labels. 1. Chloroacetyl-Substituted Phenylalanylpyrrolidines

Six analogues of thyroliberin (THR) that have a chloroacetyl substituent at the amino terminus have been prepared as potential affinity labels for the TRH receptor.These compounds are N-(chloroacetyl)-L-alanyl-L-phenylalanylpyrrolidine (ClAc-Ala-Phe-Pyrr; 14), N--L-phenylalanyl>pyrrolidine (m-ClAcBz-Phe-Pyrr; 11a), N--L-alanyl-L-phenylalanylpyrrolidine (m-ClAcBz-Ala-Phe-Pyrr; 15a), N--L-phenylalanylpyrrolidine (p-ClAcBz-Phe-Pyrr; 11b), and N--L-alanyl-L-phenylalanylpyrrolidine (p-ClAcBz-Ala-Phe-Pyrr; 15b).Pyroglutamyl-L-phenylalanylpyrrolidine was also synthesized as a model agonist.Weak agonist activity was observed for 11a, 11b, and 15b.These three analogues do not contain the amide group of the pyroglutamyl moiety that was previously thought to be essential for intrinsic activity.No significant antagonist activity was observed for these compounds at the doses tested.